Olmesartan/amlodipine: a review of its use in the management of hypertension

References

• EzzatiMLopezADRodgersAVander HoornSMurrayCJSelected major risk factors and global and regional burden of diseaseLancet200236093431347136012423980
   PubMed Web of Science ®Google Scholar
• World Health Organization. Reducing Risks, Promoting Healthy LifeThe World Health Report Available at: http://www.who.int/whr/2002/en/whr02_en.pdf. Accessed September 17, 2008.
   Google Scholar
• KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet2005365945521722315652604
   PubMed Web of Science ®Google Scholar
• OngKLCheungBMManYBLauCPLamKSPrevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004Hypertension2007491697517159087
   PubMed Web of Science ®Google Scholar
• Wolf-MaierKCooperRSBanegasJRHypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United StatesJAMA2003289182363236912746359
   PubMed Web of Science ®Google Scholar
• SmithDHComparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertensionDrugs20086891207122518547132
   PubMed Web of Science ®Google Scholar
• KannelWBBlood pressure as a cardiovascular risk factor: prevention and treatmentJAMA199627520157115768622248
   PubMed Web of Science ®Google Scholar
• KlagMJWheltonPKRandallBLBlood pressure and end-stage renal disease in menN Engl J Med1996334113187494564
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens2009272121215819838131
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA2002288232981299712479763
   PubMed Web of Science ®Google Scholar
• DolorRJYancyWSJrOwenWFHypertension Improvement Project (HIP): study protocol and implementation challengesTrials2009101319245692
   PubMed Web of Science ®Google Scholar
• GueyffierFFromentAGoutonMNew meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefitJ Hum Hypertens1996101188642184
   PubMed Web of Science ®Google Scholar
• PsatyBMSmithNLSiscovickDSHealth outcomes associated with antihypertensive therapies used as first–line agents. A systematic review and meta-analysisJAMA199727797397459042847
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research GroupPrevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research GroupJAMA199126524325532642046107
   PubMed Web of Science ®Google Scholar
• WangYRAlexanderGCStaffordRSOutpatient hypertension treatment, treatment intensification, and control in Western Europe and the United StatesArch Intern Med2007167214114717242314
   PubMedGoogle Scholar
• Wolf-MaierKCooperRSKramerHHypertension treatment and control in five European countries, Canada, and the United StatesHypertension2004431101714638619
   PubMed Web of Science ®Google Scholar
• CushmanWCBasileJAchieving blood pressure goals: why aren’t we?J Clin Hypertens (Greenwich)200681286587217170612
   PubMedGoogle Scholar
• PhillipsLSBranchWTCookCBClinical inertiaAnn Intern Med2001135982583411694107
   PubMed Web of Science ®Google Scholar
• SprangerCBRiesAJBergeCARadfordNBVictorRGIdentifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertensionAm J Med20041171141815210383
   PubMed Web of Science ®Google Scholar
• KreutzRPharmacogenetics of antihypertensive drug responseCurr Hypertens Rep200461152014972084
   PubMed Web of Science ®Google Scholar
• NeutelJMLow-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk managementAm J Hypertens1999128 Pt 273S79S10478700
   PubMed Web of Science ®Google Scholar
• WaldDSLawMMorrisJKBestwickJPWaldNJCombination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trialsAm J Med2009122329030019272490
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• CushmanWCEvansGWByingtonRPEffects of intensive blood-pressure control in type 2 diabetes mellitusN Engl J Med2010362171575158520228401
   PubMed Web of Science ®Google Scholar
• GradmanAHBasileJNCarterBLCombination therapy in hypertensionJ Am Soc Hypertens201042909820400053
   PubMed Web of Science ®Google Scholar
• BramlagePFixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertensionExpert Opin Pharmacother200910111755176719538001
   PubMed Web of Science ®Google Scholar
• SchmiederREThe role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigmClin Exp Hypertens2010321354220144071
   PubMed Web of Science ®Google Scholar
• GuptaAKArshadSPoulterNRCompliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysisHypertension201055239940720026768
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJMorrisJKJordanREValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBr Med J20033267404142712829555
   PubMed Web of Science ®Google Scholar
• FrishmanWHRamCVMcMahonFGComparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study GroupJ Clin Pharmacol19953511106010668626878
   PubMed Web of Science ®Google Scholar
• KuschnirEAcunaESevillaDTreatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placeboClin Ther1996186121312249001838
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• MillerDROliveriaSABerlowitzDRFinckeBGStangPLillienfeldDEAngioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitorsHypertension20085161624163018413488
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceHypertension: Management of hypertension in adults in primary care Available at: http://www.nice.org.uk/nicemedia/live/10986/30114/30114.pdf. Accessed June 9, 2010.
   Google Scholar
• FabiaMJAbdillaNOltraRFernandezCRedonJAntihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoringJ Hypertens20072571327133617563549
   PubMed Web of Science ®Google Scholar
• ColtamaiLMaillardMSimonAVogtBBurnierMComparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humansJ Hypertens201028352052620104189
   PubMed Web of Science ®Google Scholar
• HaslerCNussbergerJMaillardMForclazABrunnerHRBurnierMSustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitorClin Pharmacol Ther200578550150716321616
   PubMed Web of Science ®Google Scholar
• JonesMRSealeyJELaraghJHEffects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intakeAm J Hypertens200720890791617679042
   PubMed Web of Science ®Google Scholar
• BrunnerHRStumpeKOJanuszewiczAAntihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertensionClin Drug Invest2003237419430
   PubMed Web of Science ®Google Scholar
• OparilSWilliamsDChrysantSGMarburyTCNeutelJComparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertensionJ Clin Hypertens (Greenwich)20013528329131811588406
   PubMedGoogle Scholar
• SmithDHDubielRJonesMUse of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartanAm J Cardiovasc Drugs200551415015631537
   PubMedGoogle Scholar
• ScottLJMcCormackPLOlmesartan medoxomil: a review of its use in the management of hypertensionDrugs20086891239127218547134
   PubMed Web of Science ®Google Scholar
• HariaMWagstaffAJAmlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular diseaseDrugs19955035605868521773
   PubMed Web of Science ®Google Scholar
• ChrysantSMelinoMKarkiSLeeJHeyrmanRThe combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety studyClin Ther200830458760418498909
   PubMed Web of Science ®Google Scholar
• ChrysantSMelinoMKarkiSLeeJHeyrmanROnset of antihypertensive effect in patients with mild-to-severe hypertension treated with a combination of amlodipine besylate and olmesartan medoxomil compared with component monotherapy and placeboJ Clin Hypertens2008a26378 Suppl 1378
   Google Scholar
• OparilSLeeJKarkiSMelinoMSubgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication useJ Cardiovasc Pharmacol200954542743619730391
   PubMed Web of Science ®Google Scholar
• VolpeMBrommerPHaagUMieleCEfficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig20092911125
   PubMed Web of Science ®Google Scholar
• BarriosVBrommerPHaagUCalderonAEscobarCOlmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig2009297427439
   PubMed Web of Science ®Google Scholar
• WeirMRHsuehWANesbittSDEffects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy (late breaker at the American Society of Hypertension 25th Annual Scentific Meeting, New York)J Clin Hypertens (Greenwich)2010127536
   Google Scholar
• PunziHNeutelJMKereiakesDJEfficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) studyTher Adv Cardiovasc Dis20104420922120519261
   PubMedGoogle Scholar
• ChrysantSGOparilSMelinoMKarkiSLeeJHeyrmanREfficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertensionJ Clin Hypertens (Greenwich)200911947548219751459
   PubMed Web of Science ®Google Scholar
• HeagertyAMLaeisPHaagUOlmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy – additional effect by uptitration in patients with moderate-to-severe hypertensionJ Hypertens200927Suppl 4S283
   Google Scholar
• ParatiGBiloGOlmesartan medoxomil/amlodipine (OLM/AML) improves blood pressure (BP) control throughout 24 hours compared with AML monotherapy in patients with moderate-to-severe hypertensionJ Hypertens201028e111
   PubMed Web of Science ®Google Scholar
• HeagertyAMLaeisPHaagUOlmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy – additional effect by uptitration in patients with moderate-to-severe hypertensionJ Hypertens200927Suppl 4S283
   Google Scholar
• VolpeMMieleCHaagUEfficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term studyClin Drug Investig2009296381391
   PubMed Web of Science ®Google Scholar
• MouradJJLe JeuneSEffective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre studyClin Drug Investig2009296419425
   PubMed Web of Science ®Google Scholar
• WeirMHsuehWANesbittSDEffects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior anti-hypertensive monotherapy2010: Presented as a late breaker at the American Society of Hypertension 25th Annual Scentific Meeting and Exposition2010New York
   Google Scholar
• OpieLHPharmacological differences between calcium antagonistsEur Heart J199718Suppl AA71A799049541
   PubMedGoogle Scholar